Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission

Abstract

Kynurenic acid (KYNA) is an endogenous tryptophan (Trp) metabolite known to possess neuroprotective property. KYNA plays critical roles in nociception, neurodegeneration, and neuroinflammation. A lower level of KYNA is observed in patients with neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases or psychiatric disorders such as depression and autism spectrum disorders, whereas a higher level of KYNA is associated with the pathogenesis of schizophrenia. Little is known about the optimal concentration for neuroprotection and the threshold for neurotoxicity. In this study the effects of KYNA on memory functions were investigated by passive avoidance test in mice. Six different doses of KYNA were administered intracerebroventricularly to previously trained CFLP mice and they were observed for 24 h. High doses of KYNA (i.e., 20–40 μg/2 μL) significantly decreased the avoidance latency, whereas a low dose of KYNA (0.5 μg/2 μL) significantly elevated it compared with controls, suggesting that the low dose of KYNA enhanced memory function. Furthermore, six different receptor blockers were applied to reveal the mechanisms underlying the memory enhancement induced by KYNA. The series of tests revealed the possible involvement of the serotonergic, dopaminergic, α and β adrenergic, and opiate systems in the nootropic effect. This study confirmed that a low dose of KYNA improved a memory component of cognitive domain, which was mediated by, at least in part, four systems of neurotransmission in an animal model of learning and memory.

Galanin and Neuropeptide Y Interaction Enhances Proliferation of Granule Precursor Cells and Expression of Neuroprotective Factors in the Rat Hippocampus with Consequent Augmented Spatial Memory

“…However, aging is a significant risk for the development of cognitive decline and neurodegenerative disorders since the homeostasis of the neurogenic niche is altered. Thus, dysregulation of hippocampal neurogenesis is linked to several brain disorders, such as age-dependent cognitive decline, Alzheimer’s disease (AD), amyotrophic lateral sclerosis, Huntington’s disease, Parkinson’s disease, dementia with Lewy bodies, and frontotemporal dementia [ 6 , 8 , 9 , 10 ]. AD, the most frequent among neurodegenerative diseases, accounts for about 70% of dementia cases worldwide, that is, about 35 million people.…”

The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases

“…The reduced concentrations of the protective metabolite, picolinic acid, in CSF were sustained over two years after a suicide attempt in depressive patients. Although kynurenic acid, another metabolite of kynurenine, was not assessed in the latter study [ 57 ], it might have worked to counteract excessive NMDA receptor activation and exert a neuroprotective action [ 58 , 59 , 60 , 61 ]. An antidepressant effect of kynurenic acid is in accordance with the results from an experimental study in a rat model [ 62 ].…”

Attention Deficit Hyperactivity Disorder Assessment Based on Patient Behavior Exhibited in a Car Video Game: A Pilot Study

“…However, obtaining an early and accurate diagnosis of ADHD remains a major problem in clinical psychology and psychiatry. Although efforts are being made to develop precision diagnostics (searching for biomarkers that may be related to those impairments that affect cognitive functions [ 13 , 25 ]), currently, the diagnosis of ADHD is made through a clinical interview in which the medical professional relies on scales filled out by caregivers and teachers. This means that the diagnosis of ADHD depends on the training, experience and knowledge of the medical professional, as well as on the observation skills of the caregivers.…”